Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials

Puntos clave

• Progression-free survival 2 shows promise as a surrogate endpoint for overall survival in breast cancer trials.
• Analysis includes metrics from multiple studies, highlighting a strong correlation between PFS2 and OS outcomes.
• Results are derived from randomized controlled trials which provide a robust framework for evaluation.
• Supports the use of PFS2 to assess treatment efficacy, prioritizing patient outcomes in clinical settings.